Pre-made Olaratumab benchmark antibody ( Whole mAb, anti-PDGFRA therapeutic antibody, Anti-CD140A/PDGFR-2/PDGFR2 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Olaratumab biosimilar, Whole mAb, Anti-PDGFRA Antibody: Anti-CD140A/PDGFR-2/PDGFR2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Olaratumab, sold under the brand name Lartruvo, is a monoclonal antibody medication developed by Eli Lilly and Company for the treatment of solid tumors. It is directed against the platelet-derived growth factor receptor alpha.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-393-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Olaratumab biosimilar, Whole mAb, Anti-PDGFRA Antibody: Anti-CD140A/PDGFR-2/PDGFR2 therapeutic antibody
INN Name	Olaratumab
Target	PDGFRA
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2010
Year Recommended	2011
Companies	ImClone Systems;Eli Lilly;Institute for Clinical Oncological Research
Conditions Approved	Soft tissue sarcoma
Conditions Active	Pancreatic cancer;Solid tumours
Conditions Discontinued	Gastrointestinal stromal tumours;Glioblastoma;Non-small cell lung cancer;Ovarian cancer;Prostate cancer
Development Tech	Medarex UltiMAb Mouse